Moderna's Investigational Therapeutic mRNA-3705 in FDA's START Pilot Program

Thursday, 6 June 2024, 08:28

The U.S. Food & Drug Administration has selected Moderna's investigational therapeutic mRNA-3705 for the START Pilot Program. This collaboration signifies a significant milestone for Moderna in advancing treatment options for Methylmalonic Acidemia patients.
https://store.livarava.com/896baa35-23f9-11ef-a40f-9d5fa15a64d8.jpg
Moderna's Investigational Therapeutic mRNA-3705 in FDA's START Pilot Program

Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program

Moderna's investigational therapeutic mRNA-3705 has been chosen by the U.S. Food & Drug Administration to participate in the START Pilot Program. This selection highlights the potential of mRNA-3705 in addressing Methylmalonic Acidemia, a rare genetic disorder.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe